Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
Oncocyte Corp (Nasdaq: OCX), a diagnostics technology company, has announced its participation in 'J.P. Morgan Week' alongside the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025.
CEO Josh Riggs and CFO Andrea James will be available for one-on-one meetings with investors during the event. Interested investors can schedule meetings through Julie Silber at PCG Advisory.
Oncocyte Corp (Nasdaq: OCX), una società di tecnologia diagnostica, ha annunciato la sua partecipazione alla 'J.P. Morgan Week' in concomitanza con la 43esima Conferenza Annuale J.P. Morgan Healthcare a San Francisco dal 13 al 16 gennaio 2025.
Il CEO Josh Riggs e il CFO Andrea James saranno disponibili per incontri individuali con gli investitori durante l'evento. Gli investitori interessati possono prenotare incontri tramite Julie Silber di PCG Advisory.
Oncocyte Corp (Nasdaq: OCX), una empresa de tecnología de diagnóstico, ha anunciado su participación en la 'Semana de J.P. Morgan' junto a la 43ª Conferencia Anual de Salud de J.P. Morgan en San Francisco del 13 al 16 de enero de 2025.
El CEO Josh Riggs y la CFO Andrea James estarán disponibles para reuniones uno a uno con inversores durante el evento. Los inversores interesados pueden programar reuniones a través de Julie Silber de PCG Advisory.
온코사이티 코퍼레이션 (Nasdaq: OCX), 진단 기술 회사가 'JP 모건 주간'에 참여한다고 발표했습니다. 이는 샌프란시스코에서 열리는 제43회 연례 JP 모건 건강 회의와 함께합니다. 2025년 1월 13일부터 16일까지 진행됩니다.
CEO 조쉬 리그스와 CFO 안드레아 제임스는 행사 동안 투자자와의 일대일 미팅을 위해 참석할 것입니다. 관심 있는 투자자는 PCG 어드바이저의 줄리 실버를 통해 미팅을 일정 잡을 수 있습니다.
Oncocyte Corp (Nasdaq: OCX), une entreprise de technologie de diagnostics, a annoncé sa participation à la 'Semaine J.P. Morgan' en parallèle de la 43e Conférence Annuelle de Santé J.P. Morgan à San Francisco, du 13 au 16 janvier 2025.
Le PDG Josh Riggs et la CFO Andrea James seront disponibles pour des réunions individuelles avec les investisseurs durant l'événement. Les investisseurs intéressés peuvent planifier des réunions via Julie Silber de PCG Advisory.
Oncocyte Corp (Nasdaq: OCX), ein Unternehmen für Diagnosetechnologie, hat seine Teilnahme an der 'J.P. Morgan Woche' bekannt gegeben, die zeitgleich mit der 43. jährlichen J.P. Morgan Gesundheitskonferenz in San Francisco vom 13. bis 16. Januar 2025 stattfindet.
CEO Josh Riggs und CFO Andrea James werden während der Veranstaltung für Einzelgespräche mit Investoren zur Verfügung stehen. Interessierte Investoren können Meetings über Julie Silber von PCG Advisory vereinbaren.
- None.
- None.
January 13-16, 2025, San Francisco, CA
IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. Morgan Week,” coinciding with the 43ʳᵈ Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13-16, 2025. During this period, Oncocyte will host one-on-one meetings with interested investors.
Investors wishing to schedule a meeting are encouraged to contact Julie Silber at PCG Advisory via email at jsilber@pcgadvisory.com.
Event: “J.P. Morgan Week”
Dates: January 13-16, 2025
Location: San Francisco, CA, USA
About Oncocyte
Oncocyte is a diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:
VitaGraft Kidney™ – https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ – https://oncocyte.com/vitagraft-liver/
GraftAssure™ – https://oncocyte.com/graftassure/
DetermaIO™ – https://oncocyte.com/determa-io/
DetermaCNI™ – https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
FAQ
When is Oncocyte (OCX) participating in JP Morgan Week 2025?
Who will represent Oncocyte (OCX) at JP Morgan Week 2025?
How can investors schedule meetings with Oncocyte (OCX) during JP Morgan Week 2025?
Where will Oncocyte (OCX) host investor meetings during JP Morgan Week 2025?
